Glucagon: The Blood Sugar-Raising Peptide
Glucagon Biology
29 amino acids
Glucagon is a 29-amino-acid peptide hormone secreted by pancreatic alpha cells that functions as insulin's metabolic counterpart, raising blood glucose through glycogenolysis and gluconeogenesis.
StatPearls, Physiology of Glucagon, 2025
StatPearls, Physiology of Glucagon, 2025
View as imageInsulin gets the attention. Glucagon does the opposite job with less recognition. Secreted by pancreatic alpha cells, glucagon is a 29-amino-acid peptide hormone that raises blood glucose by stimulating glycogenolysis (glycogen breakdown) and gluconeogenesis (new glucose synthesis) in the liver. Where insulin is the storage signal, glucagon is the mobilization signal. Together, they maintain blood glucose within a narrow physiological range that the brain requires for continuous function. Glucagon's role as the primary counter-regulatory hormone protecting against hypoglycemia has been understood since the 1950s, but the peptide has recently become central to drug development for an entirely different reason: glucagon receptor activation enhances fat oxidation, increases energy expenditure, and reduces hepatic lipid accumulation. This metabolic profile has made the glucagon receptor a key component of the triple agonist drugs (GLP-1/GIP/glucagon) like retatrutide, which achieved 24.2% mean weight loss at 48 weeks in phase 2 trials, exceeding any prior pharmacological weight loss intervention.[1] This article covers glucagon from basic peptide biology through counter-regulatory physiology to the triple agonist revolution in metabolic drug development. For specific subtopics, see our articles on glucagon receptor antagonists, oxyntomodulin, the natural dual agonist, and the counter-regulatory response.
Key Takeaways
- Glucagon is a 29-amino-acid peptide from pancreatic alpha cells that raises blood glucose through hepatic glycogenolysis and gluconeogenesis, serving as insulin's metabolic counterpart
- Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, achieved 24.2% mean weight loss at 48 weeks in phase 2 and up to 71.2 lbs average weight loss in phase 3 (Eli Lilly, 2025)
- Glucagon receptor activation enhances lipid oxidation and reduces hepatic fat, explaining why adding glucagon agonism to GLP-1 drugs produces greater weight loss and liver fat reduction than GLP-1 alone
- Survodutide (dual GLP-1/glucagon agonist) acts through circumventricular organs in the brain, activating neurons that mediate appetite suppression (Zimmermann et al., 2026)
- A triple GLP-1R/Y1R/Y2R agonist decreased fentanyl-evoked dopamine release, connecting glucagon-adjacent peptide pharmacology to addiction research (Caffrey et al., 2025)
- Incretin-based dual and triple agonists represent a paradigm shift from single-target to multi-target metabolic therapy (Alavi et al., 2026; Chan et al., 2026)
Glucagon: Structure and Synthesis
Discovery and Historical Context
Glucagon was discovered in 1923 by Kimball and Murlin, who observed a hyperglycemic substance contaminating their insulin preparations. The name "glucagon" (glucose agonist) was coined to contrast with insulin's glucose-lowering effect. The peptide was sequenced in 1957 by Bromer and colleagues, making it one of the first peptide hormones to be fully characterized. For decades, glucagon was considered clinically relevant primarily as an emergency treatment for severe hypoglycemia, administered by injection to unconscious diabetic patients. The recognition of glucagon's broader metabolic roles, particularly in lipid metabolism and energy expenditure, came much later and has driven the current wave of drug development.
Glucagon is encoded by the proglucagon gene (GCG) on chromosome 2. The same gene encodes multiple bioactive peptides through tissue-specific post-translational processing. In pancreatic alpha cells, prohormone convertase 2 (PC2) processes proglucagon to yield glucagon (amino acids 33-61 of the precursor). In intestinal L-cells, prohormone convertase 1/3 (PC1/3) processes the same precursor to yield GLP-1 and GLP-2 instead. This tissue-specific processing means that a single gene produces both the glucose-raising hormone (glucagon, from the pancreas) and the glucose-lowering incretin (GLP-1, from the gut).
Glucagon is a single-chain polypeptide of 29 amino acids with a molecular weight of approximately 3,485 Da. It has no disulfide bonds and adopts an alpha-helical conformation in lipid environments, which is the receptor-binding form. The N-terminal histidine residue is critical for receptor activation; modifications at this position convert agonists to antagonists.
The glucagon receptor (GCGR) is a class B G-protein-coupled receptor expressed primarily in the liver, with lower expression in the kidney, heart, adipose tissue, brain (particularly the hypothalamus and brainstem), and the gastrointestinal tract. Receptor activation couples to Gs proteins, stimulating adenylyl cyclase and increasing intracellular cAMP. In hepatocytes, this cAMP signal activates protein kinase A, which phosphorylates and activates glycogen phosphorylase (driving glycogenolysis) and upregulates gluconeogenic enzymes (phosphoenolpyruvate carboxykinase, glucose-6-phosphatase).
The Counter-Regulatory Response
Glucagon is the first line of defense against hypoglycemia. When blood glucose drops below approximately 65-70 mg/dL, pancreatic alpha cells increase glucagon secretion. This response is remarkably fast: glucagon levels rise within 1-2 minutes of detecting hypoglycemia, and hepatic glucose output increases within 3-5 minutes. The counter-regulatory response also involves epinephrine, cortisol, and growth hormone, but glucagon is the most rapid and quantitatively important component.
In type 1 diabetes, the counter-regulatory glucagon response is often impaired or absent, creating dangerous vulnerability to hypoglycemia during insulin therapy. This impairment develops progressively and is thought to result from loss of paracrine signaling from neighboring beta cells (which normally suppress alpha cell glucagon secretion through insulin and zinc co-secretion) combined with autonomic neuropathy affecting the adrenal response.
In type 2 diabetes, the opposite problem occurs: glucagon secretion is paradoxically elevated in the fasting state and fails to suppress appropriately after meals. This hyperglucagonemia contributes to fasting hyperglycemia and postprandial glucose excursions, and it represents one of the core pathophysiological defects of T2D alongside insulin resistance and beta cell dysfunction. Roger Unger's "bihormonal hypothesis" (1975) proposed that diabetes is not simply an insulin deficiency disease but a disease of dysregulated insulin-to-glucagon ratio. This concept has been validated by decades of subsequent research and directly informs the rationale for GLP-1-based therapies, which suppress glucagon secretion as part of their glucose-lowering mechanism.
The Emergency Glucagon Kit
In clinical practice, glucagon has been available as an emergency injectable for severe hypoglycemia since the 1960s. Traditional glucagon emergency kits required reconstitution of lyophilized powder, a multi-step process that family members or bystanders found difficult to perform under stress. Recent innovations have produced nasal glucagon (Baqsimi, approved 2019) and stable liquid glucagon autoinjectors (Gvoke, approved 2019), eliminating the reconstitution step and dramatically improving usability in emergency settings.
Dasiglucagon (Zegalogue, approved 2021) is a glucagon analog with improved solubility and stability that enables a ready-to-use liquid formulation. These pharmaceutical advances reflect the ongoing importance of glucagon as a rescue medication, even as the peptide's role expands into obesity and metabolic disease treatment.
Glucagon in Exercise Physiology
During prolonged exercise, glucagon secretion increases to maintain blood glucose as muscle glycogen is depleted. The exercise-induced glucagon response is proportional to exercise intensity and duration, and it is essential for preventing exercise-induced hypoglycemia. Athletes with type 1 diabetes who lack both the insulin suppression and glucagon elevation responses during exercise are at high risk of hypoglycemia during and after physical activity.
The exercise-glucagon connection has implications for understanding the metabolic benefits of physical activity. Exercise-induced glucagon secretion promotes hepatic fatty acid oxidation, the same mechanism that makes glucagon receptor agonism attractive for treating MASLD. Regular exercise may partially replicate the liver-specific metabolic benefits of pharmacological glucagon receptor activation.
For comprehensive coverage of the peptide-mediated counter-regulatory system, see the counter-regulatory response.
Glucagon Beyond Blood Sugar
The classical view of glucagon as purely a glucose-raising hormone has given way to a more nuanced understanding of its metabolic roles.
Lipid metabolism. Glucagon receptor activation in the liver stimulates fatty acid oxidation and inhibits lipogenesis. This reduces hepatic triglyceride content and promotes the use of fat as an energy substrate. In animal models, glucagon receptor agonism reduces liver fat by 30-50%, an effect that has made the glucagon receptor attractive for treating metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD).
Energy expenditure. Glucagon increases whole-body energy expenditure through both hepatic thermogenesis and activation of brown adipose tissue. The thermogenic effect is mediated partly through FGF21 induction and partly through direct effects on mitochondrial uncoupling in hepatocytes. This calorie-burning property distinguishes glucagon from other weight loss mechanisms that work solely through appetite suppression.
Amino acid metabolism. Glucagon promotes hepatic amino acid uptake and ureagenesis. This creates a liver-alpha cell feedback axis: high circulating amino acids stimulate glucagon secretion, and glucagon stimulates hepatic amino acid clearance. Disruption of this axis (e.g., through glucagon receptor blockade) leads to hyperaminoacidemia and alpha cell hyperplasia.
Cardiac function. The glucagon receptor is expressed in cardiomyocytes, where glucagon produces positive inotropic and chronotropic effects. Intravenous glucagon has been used clinically as a cardiac stimulant in beta-blocker and calcium channel blocker overdose, where its ability to stimulate cardiac contractility independent of beta-adrenergic receptors provides a lifesaving intervention. Retatrutide showed positive inotropic effects in isolated human atrial preparations, confirming direct cardiac activity of glucagon receptor activation.[2]
Satiety signaling. Glucagon at physiological concentrations contributes to meal termination through hepatic metabolic sensing. As the liver processes nutrients after a meal, glucagon-mediated metabolic changes generate vagal afferent signals to the brainstem that promote satiety. This satiety mechanism is distinct from GLP-1's well-characterized appetite suppression and represents an independent pathway through which glucagon receptor agonism can reduce food intake.
Thermogenesis. Glucagon stimulates brown adipose tissue (BAT) activation and hepatic thermogenesis. In cold exposure, glucagon secretion increases to support both glucose mobilization and heat production. The thermogenic effect involves upregulation of mitochondrial uncoupling proteins and increased oxygen consumption in both liver and BAT. In humans, glucagon infusion increases resting energy expenditure by approximately 100-200 kcal/day, a modest but cumulative effect that contributes to the weight loss advantage of glucagon-inclusive agonists over GLP-1-only agents.
Glucagon and the Pancreatic Peptide Trio
Glucagon is one of three peptide hormones produced by the endocrine pancreas. Beta cells produce insulin (the glucose-lowering, storage-promoting hormone). Alpha cells produce glucagon (the glucose-raising, mobilization hormone). Delta cells produce somatostatin (which inhibits both insulin and glucagon secretion). The three cell types are organized in islets of Langerhans, where paracrine signaling between adjacent cells coordinates the hormonal response to nutritional state.
A fourth pancreatic peptide, amylin (IAPP), is co-secreted with insulin from beta cells and slows gastric emptying, suppresses glucagon, and promotes satiety. The interaction between glucagon and amylin is clinically relevant: amylin analogs (pramlintide) are approved for diabetes treatment partly because they suppress postprandial glucagon secretion. The newer combination of cagrilintide (an amylin analog) with semaglutide targets this axis from the amylin side.
The Triple Agonist Revolution
The recognition that glucagon receptor activation burns fat and increases energy expenditure, while GLP-1 receptor activation suppresses appetite and improves glucose tolerance, created the rationale for combining both mechanisms in a single molecule. Adding GIP receptor agonism (which enhances insulin secretion and may improve fat storage efficiency) produced the triple agonist concept.
Retatrutide
Retatrutide (LY3437943) is a GLP-1/GIP/glucagon receptor triple agonist developed by Eli Lilly. In the phase 2 trial published in the New England Journal of Medicine, retatrutide achieved 24.2% mean weight loss at 48 weeks in individuals with obesity, the highest weight loss seen with any pharmacological agent at that time.[1] In participants with type 2 diabetes, retatrutide produced 16.9% weight loss after 36 weeks.
Phase 3 results have been equally striking. In the TRIUMPH-4 trial evaluating retatrutide in adults with obesity and knee osteoarthritis, participants lost an average of 71.2 lbs, with substantial improvements in osteoarthritis pain scores. Retatrutide also markedly improved lipid profiles, reducing total cholesterol by 15-18%, LDL by 12-22%, and triglycerides by 35-40%.
A systematic review and meta-analysis of retatrutide RCTs confirmed consistent efficacy and an acceptable safety profile across studied doses and populations.[3] Retatrutide showed metabolic benefits in diet-induced obese MASH mouse models, supporting the liver-specific benefits of glucagon receptor activation.[4] Body composition analysis from the retatrutide type 2 diabetes trial showed favorable fat-to-lean mass loss ratios compared to expectations from the magnitude of weight reduction.[5]
Survodutide
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. Unlike retatrutide, survodutide does not include GIP receptor agonism, allowing researchers to isolate the contribution of glucagon receptor activation when compared to GLP-1-only agents.
Survodutide acts through circumventricular organs in the brain and activates neurons that mediate appetite suppression, demonstrating that the glucagon receptor component contributes to central appetite regulation in addition to its peripheral metabolic effects.[6] Systematic reviews of survodutide efficacy and safety confirmed meaningful weight loss and metabolic improvement.[7] Phase 3 SYNCHRONIZE trials are enrolling participants for pivotal evaluation.[8][9]
Why Glucagon Agonism Adds to GLP-1
The mechanistic rationale for adding glucagon agonism to GLP-1 drugs rests on complementary metabolic actions. GLP-1 agonism suppresses appetite and improves glucose tolerance. Glucagon agonism increases hepatic fat oxidation, raises energy expenditure, and reduces liver fat. The combination produces weight loss from both reduced energy intake (GLP-1) and increased energy expenditure (glucagon), a dual mechanism that neither agent achieves alone.
The liver fat reduction is particularly relevant for MASLD/MASH, where hepatic steatosis drives inflammation, fibrosis, and eventual cirrhosis. MASLD affects approximately 30% of the global population and has no approved pharmacotherapy with demonstrated anti-fibrotic efficacy. GLP-1 agonists alone modestly reduce liver fat (primarily through weight loss). Adding glucagon agonism directly promotes hepatic lipid oxidation through increased mitochondrial beta-oxidation and reduced de novo lipogenesis, potentially producing greater liver-specific benefit independent of total weight loss.[10] Both retatrutide and survodutide have shown liver fat reductions exceeding those achieved by semaglutide or tirzepatide alone, and dedicated MASLD trials are underway for both compounds.
The Competitive Landscape
The multi-agonist pipeline has become intensely competitive. In addition to retatrutide (GLP-1/GIP/glucagon) and survodutide (GLP-1/glucagon), several other compounds are in development. Mazdutide (Innovent/Lilly) is another GLP-1/glucagon dual agonist with phase 3 data in Chinese populations. Pemvidutide (Altimmune) targets GLP-1/glucagon for MASLD specifically. The melanocortin 4/GLP-1 receptor dual agonist approach takes a different direction, combining appetite suppression through hypothalamic MC4R activation with GLP-1-mediated metabolic improvement.
The differentiation between these agents will ultimately rest on clinical outcomes data rather than receptor pharmacology. Weight loss magnitude, body composition quality (fat vs. lean mass loss), liver-specific endpoints, cardiovascular outcomes, and tolerability profiles will determine which multi-agonist strategy prevails. The glucagon receptor component appears critical for maximizing weight loss and liver fat reduction, but its contribution to cardiovascular risk (positive or negative) will be decisive for long-term prescribing patterns.
Glucagon Measurement: A Technical Challenge
Accurately measuring circulating glucagon concentrations has been technically challenging since the peptide's discovery. Early radioimmunoassays cross-reacted with other proglucagon-derived peptides (GLP-1, GLP-2, oxyntomodulin, glicentin), overestimating true glucagon concentrations. Sandwich ELISAs using N-terminal and C-terminal specific antibodies have improved specificity, but standardization across laboratories remains incomplete. This measurement uncertainty has complicated the interpretation of studies reporting glucagon levels in health and disease, and it means that some historical data on glucagon physiology may need revision with modern assay technology.
Glucagon Receptor Antagonists
While triple agonists exploit glucagon receptor activation for metabolic benefit, an opposing strategy blocks the glucagon receptor to reduce hepatic glucose production in type 2 diabetes. Glucagon receptor antagonists lower fasting blood glucose by preventing glucagon's glycogenolytic and gluconeogenic effects.
The challenge with glucagon receptor antagonism is the liver-alpha cell feedback axis. Blocking the glucagon receptor prevents hepatic amino acid clearance, leading to hyperaminoacidemia, which stimulates alpha cell proliferation and further glucagon secretion. This compensatory hyperglucagonemia can drive alpha cell hyperplasia and potentially alpha cell neoplasia, limiting the therapeutic window of pure glucagon receptor antagonists.
Several glucagon receptor antagonists have entered clinical trials for type 2 diabetes. LY2409021 (Eli Lilly) and volagidemab (REMD Biotherapeutics, a monoclonal antibody) demonstrated glucose-lowering efficacy but also produced dose-dependent increases in liver enzymes, LDL cholesterol, and alpha cell mass. These on-target side effects reflect the fundamental biology: blocking glucagon's hepatic effects disrupts amino acid clearance and lipid metabolism in ways that create new clinical problems.
The strategic question is whether partial glucagon receptor antagonism, sufficient to reduce fasting glucose without triggering the full compensatory response, could achieve a useful therapeutic window. This remains unresolved.
For dedicated coverage, see glucagon receptor antagonists.
Evidence Gaps and Open Questions
The cardiovascular safety of chronic glucagon receptor activation is the most pressing unanswered question. Glucagon increases heart rate and has inotropic effects. Long-term stimulation of the glucagon receptor through triple agonists could theoretically produce cardiac hypertrophy or arrhythmias. Cardiovascular outcome trials for retatrutide and survodutide are planned but not yet reported.
The optimal ratio of GLP-1, GIP, and glucagon receptor activation for different clinical indications is unknown. Obesity, type 2 diabetes, and MASLD may each require different receptor activation profiles. Current triple agonists use fixed ratios, but future personalized approaches could titrate each component independently.
The interaction between glucagon receptor activation and muscle metabolism in the context of weight loss is underexplored. Glucagon promotes amino acid catabolism in the liver, which could theoretically exacerbate the lean mass loss seen with GLP-1 RA-driven weight reduction. Whether the energy expenditure benefits of glucagon agonism offset any additional catabolic effect on muscle has not been determined.
The role of central glucagon receptor signaling in appetite, reward, and addiction remains an emerging field. Survodutide's demonstrated central nervous system activity raises the question of whether glucagon receptor activation in the brain contributes to the broader behavioral effects reported with incretin-based therapies. A triple GLP-1R/Y1R/Y2R agonist was shown to decrease fentanyl-evoked dopamine release, connecting multi-peptide receptor pharmacology to addiction neuroscience through mechanisms that include but are not limited to glucagon receptor signaling.[13]
The long-term effects of chronic glucagon receptor activation on liver health present a paradox. Short-term glucagon agonism reduces liver fat and improves hepatic metabolic function. But the liver is also the primary site of glucagon's glycogenolytic and gluconeogenic actions, and chronic stimulation of these pathways could theoretically cause hepatocyte stress or promote hepatic glucose overproduction in diabetic patients. Whether the fat-reducing benefits outweigh the glucose-raising risk over years of treatment is a key question for the ongoing phase 3 programs.
Oxyntomodulin, a 37-amino-acid peptide naturally produced by intestinal L-cells, is a weaker endogenous dual agonist of both the GLP-1 and glucagon receptors. It represents nature's version of the dual agonist concept that survodutide replicates pharmacologically. Understanding oxyntomodulin's physiological role may inform the optimal dosing and receptor activation ratios for synthetic dual and triple agonists. For dedicated coverage, see oxyntomodulin, the natural dual agonist.
The relationship between glucagon and other gut satiety peptides like CCK (cholecystokinin) deserves mention. CCK was the first satiety peptide discovered and acts through vagal afferent mechanisms similar to glucagon's hepatic satiety signaling. The two peptides may produce additive satiety effects through convergent vagal pathways, though this interaction has not been systematically studied in the context of multi-agonist drug development.
The Bottom Line
Glucagon is a 29-amino-acid pancreatic peptide that raises blood sugar, promotes fat oxidation, and increases energy expenditure. Once viewed solely as insulin's counterpart, glucagon is now a key therapeutic target in triple agonist drugs like retatrutide (24.2% weight loss in phase 2) and dual agonists like survodutide. The glucagon receptor's ability to drive hepatic fat reduction makes it particularly relevant for MASLD. Cardiovascular safety of chronic glucagon receptor activation is the critical unknown ahead of large outcome trials.